GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lucira Health Inc (OTCPK:LHDXQ) » Definitions » Debt-to-EBITDA

Lucira Health (Lucira Health) Debt-to-EBITDA : -0.10 (As of Sep. 2022)


View and export this data going back to 2021. Start your Free Trial

What is Lucira Health Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Lucira Health's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2022 was $2.3 Mil. Lucira Health's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2022 was $45.8 Mil. Lucira Health's annualized EBITDA for the quarter that ended in Sep. 2022 was $-496.6 Mil. Lucira Health's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2022 was -0.10.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Lucira Health's Debt-to-EBITDA or its related term are showing as below:

LHDXQ's Debt-to-EBITDA is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.21
* Ranked among companies with meaningful Debt-to-EBITDA only.

Lucira Health Debt-to-EBITDA Historical Data

The historical data trend for Lucira Health's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lucira Health Debt-to-EBITDA Chart

Lucira Health Annual Data
Trend Dec18 Dec19 Dec20 Dec21
Debt-to-EBITDA
-0.70 -0.14 -0.69 -0.05

Lucira Health Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.03 -0.11 0.50 -0.62 -0.10

Competitive Comparison of Lucira Health's Debt-to-EBITDA

For the Medical Devices subindustry, Lucira Health's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lucira Health's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Lucira Health's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Lucira Health's Debt-to-EBITDA falls into.



Lucira Health Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Lucira Health's Debt-to-EBITDA for the fiscal year that ended in Dec. 2021 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.609 + 1.22) / -61.136
=-0.05

Lucira Health's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2022 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(2.316 + 45.775) / -496.636
=-0.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2022) EBITDA data.


Lucira Health  (OTCPK:LHDXQ) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Lucira Health Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Lucira Health's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Lucira Health (Lucira Health) Business Description

Traded in Other Exchanges
N/A
Address
1412 62nd Street, Emeryville, CA, USA, 94608
Lucira Health Inc is a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits. It has developed a testing platform that produces high-complexity-laboratory-accurate molecular testing in a single-use and user-friendly test kit that is powered by two AA batteries and fit in the palm of a hand. The company's initial focus is within respiratory diseases, and initially for COVID-19 and influenza Types A and B indications.
Executives
Anthony Joseph Allen officer: Chief Operations Officer 1412 62ND STREET, EMERYVILLE CA 94608
Epq Llc, Lcovd Safe Ps other: Less than 10% owner 9650 GATEWAY DRIVE, SUITE 200, RENO NV 89521
Chad Boeding other: CEO of 10% owner ONE LOMBARD STREET, SUITE 200, SAN FRANCISCO CA 94111
Epiq Capital Group, Llc 10 percent owner ONE LOMBARD STREET, SUITE 200, SAN FRANCISCO CA 94111
Epq Llc, Lcovd Ps 10 percent owner 9650 GATEWAY DRIVE, SUITE 200, RENO NV 89521
Epq Llc, Lflu Ps other: Less than 10% owner 9650 GATEWAY DRIVE, SUITE 200, RENO NV 89521
Epq Llc, Ltest Ps other: Less than 10% Owner 9650 GATEWAY DRIVE, SUITE 200, RENO NV 89521
Richard Clavano Narido officer: Interim CFO 12 HANSEN CT, MORAGA CA 94556
Ghazi Kashmolah officer: Ex. VP &Chief Quality Officer 1412 62ND STREET, EMERYVILLE CA 94608
Kevin Walter Collins officer: Chief Revenue Officer C/O LUCIRA HEALTH, INC., 1412 62ND STREET, EMERYVILLE CA 94608
Dan George officer: CFO and Treasurer 1412 62ND STREET, EMERYVILLE CA 94608
Erik T. Engelson director, officer: President and Chief Executive 1412 62ND STREET, EMERYVILLE CA 94608
Debkishore Mitra director, officer: Chief Technology Officer 1412 62ND STREET, EMERYVILLE CA 94608
Tamanna Prashar officer: Vice President 1412 62ND STREET, EMERYVILLE CA 94608
Alison Mccauley director C/O LUCIRA HEALTH, INC., 1412 62ND STREET, EMERYVILLE CA 94608